Decision Diagnostics (OTC: DECN) CEO Keith Berman discusses the company’s products targeting the $25 billion global diabetes monitoring market, and the company’s path to achieving $100 million+ revenues within next 2 years.

http://www.wallstreetreporter.com/2018/11/dec...ng-market/

(NO log-in or subscription required)